US Drug Recall Register
Class II · Moderate risk Ongoing Initiated Apr 21, 2022 (4 years ago)

Lidocaine Hydrochloride Topical Solution USP 4%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

What was recalled

Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL bottle, Rx only, Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Distributed by: McKesson Corporation dba Sky Packaging 4071 Southridge Blvd., Suite 101 Memphis, TN 38141, NDC 63739-977-64

Recalling firm
McKesson Corporation dba McKesson Drug Company
NDC code
63739-977-64
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0848-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Chloride recalls

See all
Class II · Moderate risk Ongoing

Clindamycin Palmitate Hydrochloride for Oral Solution

Reason Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.

Heritage Pharmaceuticals Inc NDC 23155-603-51 D-0768-2026
Class II · Moderate risk Ongoing

Dicyclomine Hydrochloride Capsules

Reason shortfill; reports of empty capsules.

Aurobindo Pharma USA Inc NDC 59651-719-99 D-0733-2026
Class II · Moderate risk Ongoing

Naropin

Reason Presence of Particulate Matter: Hair was found in products

Fresenius Kabi USA, LLC D-0727-2026
Class II · Moderate risk Ongoing

Rohto Cooling Eye Drops Cool Relief

Reason Lack of Assurance of Sterility

Rohto-Mentholatum (Vietnam) Co., Ltd. NDC 10742-8141-1 D-0722-2026
Class II · Moderate risk Ongoing

Rohto Cooling Eye Drops Optic Glow

Reason Lack of Assurance of Sterility

Rohto-Mentholatum (Vietnam) Co., Ltd. NDC 10742-8160-1 D-0718-2026